RegeneRx
Rockville
About RegeneRx
RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (T╬▓4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications. RegeneRx’s management team is focused on moving three distinct T╬▓4-based drug candidates through the clinic: RGN-137, RGN-259 and RGN-352. RegeneRx also holds over 60 issued patents or filed patent applications worldwide in order to enable and protect multiple indications and applications for its product candidates. In addition to T╬▓4, RegeneRx is developing T╬▓4 peptide fragments for cosmeceutical applications, separate and distinct from the pharmaceutical peptide and formulations. RegeneRx intends to pursue strategic business relationships to develop these smaller peptides for the cosmeceutical market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $11.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2021)
- Ticker: otcqb:RGRX
- Website: regenerx.com
- Phone: (502)569-1059
Industries & Categories
Biopharma, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/regenerx-2250958 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.